Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 6/20 | 0.53 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | GLP1R | P43220 | 1/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.49 |
| ▸ | GIPR | P48546 | 1/20 | 0.49 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 5/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14479398 | 0.94 | VIPR2 (0.51) | TFPIIL23RVIPR1F2GLP1R | |
| SCHEMBL14479362 | 0.87 | NPY4R (0.56) | TFPIGLP1RGCGRGIPRKISS1R | |
| SCHEMBL10169074 | 0.87 | TFPI (0.57) | TFPIIL23RVIPR1F2VIPR2 | |
| SCHEMBL14479391 | 0.87 | TFPI (0.67) | TFPIKISS1RNR3C1 | |
| SCHEMBL14479386 | 0.87 | TFPI (0.67) | TFPIKISS1RNR3C1 | |
| SCHEMBL14479348 | 0.86 | NPY4R (0.58) | TFPI | |
| SCHEMBL16299158 | 0.86 | TFPI (0.55) | TFPIIL23RVIPR1F2VIPR2 | |
| SCHEMBL16299105 | 0.85 | TFPI (0.59) | TFPIVIPR1F2VIPR2 | |
| SCHEMBL16299171 | 0.85 | TFPI (0.59) | TFPIVIPR1F2VIPR2 | |
| SCHEMBL14479438 | 0.85 | IL23R (0.61) | TFPIIL23RGLP1RGCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9155795-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130005944-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005944-A1 | CXCR4 Receptor Compounds | CXCL12, CXCR4, CCR5 | TFPI 1747/4885IL23R 647/4885VIPR1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.